Latest Focus in Novel Perspectives of Imeglimin as Anti-Diabetic Agent

Bando H

Published on: 2024-10-15

Abstract

As an oral hypoglycemic agent (OHA), imeglimin (Twymeeg) has been developed and its latest focus in research development would be introduced. It is classified as glimins, and has dual effects of increasing insulin secretion and decreasing insulin resistance through mitochondrial pathway. It raises insulin action by changing in insulin signaling in both hepatocyte and skeletal muscle. For comparative study of providing imeglimin for 6 months, the strength of quadriceps knee extension showed +13% vs +2.1%, in imeglimin vs control group (p=0.022), respectively. Chronic effect of imeglimin on mitochondrial quality control (mQC) in diabetic beta-cell has been studied at present.